Coronell-Rodriguez, Wilfrido http://orcid.org/0000-0003-1110-537X
Caceres, Diana C.
Cintra, Otavio http://orcid.org/0000-0002-3485-8780
Guzman-Holst, Adriana http://orcid.org/0000-0002-6753-2541
Funding for this research was provided by:
GlaxoSmithKline Biologicals
Article History
Received: 19 August 2023
Accepted: 19 October 2023
First Online: 15 November 2023
Declarations
:
: Diana C. Caceres, Otavio Cintra, and Adriana Guzman-Holst are employed by and hold shares in GSK. Otavio Cintra also discloses being a shareholder in Haleon. Wilfrido Coronell-Rodriguez discloses payments from Sanofi Pasteur for being a speaker and payments from GSK and Sanofi Pasteur for participation on an Advisory Board. The authors declare no other financial and non-financial relationships and activities.
: Ethics committee approval was not required for this study as it was a retrospective secondary database analysis of publicly available anonymized data, either directly accessible or requested through the Law of Transparency, from the National Health Institute of Colombia [CitationRef removed]. Disclosure recommendations [CitationRef removed] were taken into consideration when analyzing and reporting the anonymized aggregated secondary database provided by Dr. Wilfrido Coronell from Cartagena. We obtained this information from the epidemiology service of each institution, from the surveillance system registry (SIVIGILA), and from the medical histories of the patients with the endorsement of each institution and the approval of the ethics committee at the Faculty of Medicine of the University of Cartagena.